Market Cap 1.99B
Revenue (ttm) 63.72M
Net Income (ttm) -193.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -303.69%
Debt to Equity Ratio 0.23
Volume 8,120,300
Avg Vol 2,622,026
Day's Range N/A - N/A
Shares Out 174.00M
Stochastic %K 33%
Beta 1.45
Analysts Strong Sell
Price Target $19.31

Company Profile

Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis. It is also developing AXPAXLI, an axitinib intravitreal hydrogel that i...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 357 4000
Fax: 781 275 7562
Address:
15 Crosby Drive, Bedford, United States
highnihilism
highnihilism Oct. 3 at 7:20 PM
$RIO Rio Tinto Trades: 318 | Total $: 485.5 K | 0.14 × 90-Day Avg $: 3.43 M | Call $: 284.3 K | Put $: 201.2 K | Single-Leg: 93% | Multi-Leg: 6% | Contingent: 1% $OCUL Ocular Therapeutix Trades: 126 | Total $: 363.6 K | 1.47 × 90-Day Avg $: 248.2 K | Call $: 284.1 K | Put $: 79.5 K | Single-Leg: 100% | Multi-Leg: 0% $GLNG Golar LNG Trades: 357 | Total $: 729.4 K | 1.02 × 90-Day Avg $: 714.8 K | Call $: 283.6 K | Put $: 445.8 K | Single-Leg: 70% | Multi-Leg: 30% $NPWR Net Power Trades: 270 | Total $: 283.3 K | 2.29 × 90-Day Avg $: 123.6 K | Call $: 282 K | Put $: 1.4 K | Single-Leg: 99% | Multi-Leg: 1%
0 · Reply
highnihilism
highnihilism Oct. 3 at 7:14 PM
$AISP Airship AI Trades: 459 | Total $: 295.4 K | 3.09 × 90-Day Avg $: 95.6 K | Call $: 285.9 K | Put $: 9.5 K | Single-Leg: 94% | Multi-Leg: 5% $EQX Equinox Gold Trades: 1,142 | Total $: 333.3 K | 0.35 × 90-Day Avg $: 964.9 K | Call $: 284.5 K | Put $: 48.8 K | Single-Leg: 98% | Multi-Leg: 2% $MOS Mosaic Trades: 509 | Total $: 370.6 K | 0.20 × 90-Day Avg $: 1.88 M | Call $: 284.1 K | Put $: 86.5 K | Single-Leg: 89% | Multi-Leg: 11% $OCUL Ocular Therapeutix Trades: 125 | Total $: 363.5 K | 1.46 × 90-Day Avg $: 248.2 K | Call $: 284 K | Put $: 79.5 K | Single-Leg: 100% | Multi-Leg: 0%
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 6:08 PM
$OCUL: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $10 Exp on 01/15/2027 with Premium of $50K and showing BULLISH Sentiment
0 · Reply
IN0V8
IN0V8 Oct. 3 at 4:48 PM
$OCUL Watch / Opportunity Piper Sandler raises target price to $31 from $21
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 4:35 PM
$OCUL I don’t think they ever intended to execute commercially by themselves. That is why this fundraising without any discount should lead to a partnership.
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 4:32 PM
$OCUL For me, a shelf offering with absolutely no discount is totally unprecedented and I have never seen it at this scale, especially with a non-profitable biotech. An important piece of news explaining this move should be announced now
0 · Reply
TickrTalk0007
TickrTalk0007 Oct. 3 at 4:08 PM
$OCUL fundamental problem with the price targets is they are increasing the sales forecasts to assume Axpaxli will take 50% of the market of $8B anti-VEGFs in the US. ex-US this drug wont succeed and the team wont be able to execute commercially on a global level anyway.
1 · Reply
schultzeee
schultzeee Oct. 3 at 2:21 PM
$OCUL price targets that have been issued this week range from $18 to $31. The average pt is now $24.40 Piper: $31 Citizens: $29 Baird: $24 Needham: $20 BOA: $18 I expect us to start inching closer to those two low price targets over the remainder of 2025.
0 · Reply
lilcapman
lilcapman Oct. 3 at 1:24 PM
$OCUL https://x.com/zipjet/status/1974082245666238542
0 · Reply
notreload_ai
notreload_ai Oct. 3 at 1:07 PM
Piper Sandler raised $OCUL stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data. https://notreload.xyz/ocular-therapeutix-price-target-sales-forecast-raised/
1 · Reply
Latest News on OCUL
Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript

Mar 3, 2025, 10:16 AM EST - 7 months ago

Ocular Therapeutix, Inc. (OCUL) Q4 2024 Earnings Call Transcript


Ocular Is Now Thoroughly Derisked

Dec 30, 2024, 12:16 PM EST - 9 months ago

Ocular Is Now Thoroughly Derisked


Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 10:34 AM EST - 11 months ago

Ocular Therapeutix, Inc. (OCUL) Q3 2024 Earnings Call Transcript


Ocular Therapeutix™ Reports Second Quarter 2024 Results

Aug 7, 2024, 7:10 AM EDT - 1 year ago

Ocular Therapeutix™ Reports Second Quarter 2024 Results


Ocular Therapeutix® to Host Investor Day on June 13, 2024

Jun 5, 2024, 7:30 AM EDT - 1 year ago

Ocular Therapeutix® to Host Investor Day on June 13, 2024


Ocular Therapeutix™ Reports First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

Ocular Therapeutix™ Reports First Quarter 2024 Results


highnihilism
highnihilism Oct. 3 at 7:20 PM
$RIO Rio Tinto Trades: 318 | Total $: 485.5 K | 0.14 × 90-Day Avg $: 3.43 M | Call $: 284.3 K | Put $: 201.2 K | Single-Leg: 93% | Multi-Leg: 6% | Contingent: 1% $OCUL Ocular Therapeutix Trades: 126 | Total $: 363.6 K | 1.47 × 90-Day Avg $: 248.2 K | Call $: 284.1 K | Put $: 79.5 K | Single-Leg: 100% | Multi-Leg: 0% $GLNG Golar LNG Trades: 357 | Total $: 729.4 K | 1.02 × 90-Day Avg $: 714.8 K | Call $: 283.6 K | Put $: 445.8 K | Single-Leg: 70% | Multi-Leg: 30% $NPWR Net Power Trades: 270 | Total $: 283.3 K | 2.29 × 90-Day Avg $: 123.6 K | Call $: 282 K | Put $: 1.4 K | Single-Leg: 99% | Multi-Leg: 1%
0 · Reply
highnihilism
highnihilism Oct. 3 at 7:14 PM
$AISP Airship AI Trades: 459 | Total $: 295.4 K | 3.09 × 90-Day Avg $: 95.6 K | Call $: 285.9 K | Put $: 9.5 K | Single-Leg: 94% | Multi-Leg: 5% $EQX Equinox Gold Trades: 1,142 | Total $: 333.3 K | 0.35 × 90-Day Avg $: 964.9 K | Call $: 284.5 K | Put $: 48.8 K | Single-Leg: 98% | Multi-Leg: 2% $MOS Mosaic Trades: 509 | Total $: 370.6 K | 0.20 × 90-Day Avg $: 1.88 M | Call $: 284.1 K | Put $: 86.5 K | Single-Leg: 89% | Multi-Leg: 11% $OCUL Ocular Therapeutix Trades: 125 | Total $: 363.5 K | 1.46 × 90-Day Avg $: 248.2 K | Call $: 284 K | Put $: 79.5 K | Single-Leg: 100% | Multi-Leg: 0%
0 · Reply
SweepCastApp
SweepCastApp Oct. 3 at 6:08 PM
$OCUL: Unusual Options Activity Alerted CALL flow observed 100x contracts at Strike price of $10 Exp on 01/15/2027 with Premium of $50K and showing BULLISH Sentiment
0 · Reply
IN0V8
IN0V8 Oct. 3 at 4:48 PM
$OCUL Watch / Opportunity Piper Sandler raises target price to $31 from $21
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 4:35 PM
$OCUL I don’t think they ever intended to execute commercially by themselves. That is why this fundraising without any discount should lead to a partnership.
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 4:32 PM
$OCUL For me, a shelf offering with absolutely no discount is totally unprecedented and I have never seen it at this scale, especially with a non-profitable biotech. An important piece of news explaining this move should be announced now
0 · Reply
TickrTalk0007
TickrTalk0007 Oct. 3 at 4:08 PM
$OCUL fundamental problem with the price targets is they are increasing the sales forecasts to assume Axpaxli will take 50% of the market of $8B anti-VEGFs in the US. ex-US this drug wont succeed and the team wont be able to execute commercially on a global level anyway.
1 · Reply
schultzeee
schultzeee Oct. 3 at 2:21 PM
$OCUL price targets that have been issued this week range from $18 to $31. The average pt is now $24.40 Piper: $31 Citizens: $29 Baird: $24 Needham: $20 BOA: $18 I expect us to start inching closer to those two low price targets over the remainder of 2025.
0 · Reply
lilcapman
lilcapman Oct. 3 at 1:24 PM
$OCUL https://x.com/zipjet/status/1974082245666238542
0 · Reply
notreload_ai
notreload_ai Oct. 3 at 1:07 PM
Piper Sandler raised $OCUL stock target to $31 and boosted the AXPAXLI sales forecast to $3.2B due to promising eye drug trial data. https://notreload.xyz/ocular-therapeutix-price-target-sales-forecast-raised/
1 · Reply
TickrTalk0007
TickrTalk0007 Oct. 3 at 1:05 PM
$OCUL as a rule of thumb, it's pay to play....all the banks involved in the offering will provide coverage and banks that want their business will cover them and do upgrades. None of these banks actually believe the drug will sell for $1B
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 12:31 PM
$OCUL A separate SEC filing to confirm the closing of the offering is optional — companies are required to file at pricing, but not necessarily at settlement unless they consider the closing itself to be a material event.
1 · Reply
SmokenTuna
SmokenTuna Oct. 3 at 12:15 PM
$OCUL if you don’t have X.
0 · Reply
TickrTalk0007
TickrTalk0007 Oct. 3 at 11:57 AM
$OCUL offering hasn’t closed…it was supposed to close on Oct 1 probably do a filing after hours today
1 · Reply
JarvisFlow
JarvisFlow Oct. 3 at 11:43 AM
Baird has updated their rating for Ocular Therapeutix ( $OCUL ) to Outperform with a price target of 24.
0 · Reply
lilcapman
lilcapman Oct. 3 at 11:05 AM
$OCUL https://x.com/semodough/status/1974062480214381044
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 9:43 AM
$OCUL If the logic is a GIA, it means they’ll have to do another capital increase, and it will be hard to place with investors who already got screwed once.
2 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 9:21 AM
$OCUL A 20% dilutive capital raise without any discount is absolutely unprecedented for a biotech of this size, it is extraordinary and almost inconceivable that five major banks would agree to place such an offering without a clear catalyst for a non profitable biotech. This kind of transaction simply does not happen in normal market conditions.
3 · Reply
BioTechHealthX
BioTechHealthX Oct. 3 at 8:03 AM
$OCUL Ocular Therapeutix offers 37.9M shares at $12.53, securing $475M to advance Axpaxli for wet AMD and NPDR in pivotal Phase 3 studies. https://biotechhealthx.com/biotech-news/ocular-therapeutix-ocul-raises-475m-to-fund-phase-3-axpaxli-trials/
0 · Reply
Fairvalue10
Fairvalue10 Oct. 3 at 7:01 AM
$OCUL It is hardly credible that five banks would have managed such a capital raise without any discount solely on the basis of “positive data” or a simple Investor Day. The market would normally have demanded a 10–15% discount given the size of the raise, especially for a company like Ocular that is not yet profitable. The logic points instead to a transformative event in the background.
0 · Reply
BJM111
BJM111 Oct. 3 at 2:34 AM
$OCUL I remember listening to a talk by a manager at opaleye who seemed to have a lot of influence at ocular. His philosophy was in health care don’t wait until you need cash to raise. Raise money when you don’t have to. The raise stings a bit but it is out of the way. In 4 months it will be ancient history. There will be nothing to take the wind out of the sails of a positive SOL-1 readout. Plus we will get NPDR enrollment updates as further catalysts much sooner. My confidence is as high as ever.
2 · Reply
Harvo
Harvo Oct. 3 at 12:47 AM
0 · Reply